ALK-Positive Non-Small Cell Lung Cancer Overview
Learn About ALK-Positive Non-Small Cell Lung Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Of Miami
Estelamari Rodriguez is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Rodriguez and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Squamous Cell Lung Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Rodriguez is currently accepting new patients.
University Of Miami
Dao Nguyen is a Thoracic Surgeon and a General Surgeon in Miami, Florida. Dr. Nguyen and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Lung Adenocarcinoma, Thymectomy, and Endoscopy. Dr. Nguyen is currently accepting new patients.
University Of Miami
Gilberto Lopes is an Oncologist in Miami, Florida. Dr. Lopes and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Colorectal Cancer. Dr. Lopes is currently accepting new patients.
Summary: The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
Summary: This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific ty...